Current Issue : April - June Volume : 2020 Issue Number : 2 Articles : 5 Articles
Resveratrol has been reported to be beneficial against diabetes complications. The objective\nof this study was to evaluate the efficacy of resveratrol in decreasing hyperglycemia in patients with\ntype 1 diabetes (T1D) by a preliminary investigation designed as an exploratory clinical trial. Thirteen\npatients with T1D from both the sexes participated in this trial. All patients received resveratrol in 500\nmg capsules, twice daily for 60 days. Bodyweight, fasting blood sugar (FBS), hemoglobin A1c (HbA1c),\ninsulin, homeostasis model of assessment for insulin resistance (HOMA-IR), homeostasis model of\nassessment for Beta-cell function (HOMA-Beta), and markers of liver and kidney damage, inflammation,\nand oxidative stress were measured before the intervention, at 30 days and at 60 days. Resveratrol\nsupplementation for 60 days significantly decreased FBS and HbA1c in comparison with the baseline\nvalues. Resveratrol treatment also resulted in a decrease in the level of a marker for oxidative stress,\nmalondialdehyde, and an increase in total antioxidant capacity in T1D patients. Insulin, HOMA-IR,\nHOMA-Beta, and markers of liver and kidney function and inflammation were not significantly affected\nby resveratrol treatment. Overall, the results showed that 60 days of resveratrol supplementation\nexerted strong antidiabetic and antioxidant effects in patients with T1D....
Objective: Chronic functional constipation is a frequent condition. The aim of the study\nwas to evaluate the efficacy of the probiotic Lactobacillus (L.) reuteri DSM 17938 and magnesium\noxide (MgO) for relieving chronic functional constipation in children. Study design: A prospective,\ndouble-blind, placebo-controlled, randomized, and parallel-group trial was conducted in five\npediatric outpatient clinics in Japan. Sixty patients who were more than six months old and under\nsix years of age with a diagnosis of functional constipation according to Rome IV criteria were\nrandomly divided into three groups: group A (n = 20) received L. reuteri DSM 17938 and lactose\nhydrate as a placebo of MgO; group B (n = 19) received L. reuteri DSM 17938 and MgO; and group\nC (n = 21) received a placebo of L. reuteri DSM 17938 and MgO. Results: All three groups exhibited\nsignificant improvement in defecation frequency in the fourth week compared with the baseline...............
One of the most common post-operative complications of tooth extraction is pain.\nOral analgesics, namely loxoprofen sodium and diclofenac potassium, are often prescribed; however,\nthe efficacy of these drugs irrespective of gender and type of extraction has not been tested. Therefore,\nthis study aimed to compare the efficacy of these two drugs in post-dental extraction pain relief among\nmale and female patients in cases of simple and surgical tooth extraction. A single-center, triple-blind,\nrandomized clinical trial was conducted among 100 male and female patients who underwent\ntooth extraction at Taibah University Dental College and Hospital in Al-Madinah, Saudi Arabia.\nThe patients reported their pain post-operatively after 6 hours and every 12 h for 3 days using the\nVerbal Descriptor Scale (e.g., â??no painâ?, â??mild painâ?). Descriptive statistics and chi-square tests were\nrun to analyze the data. An equal number of patients received either the drug loxoprofen sodium\nor diclofenac potassium and completed the study follow-up. Patients allocated to the diclofenac\npotassium drug group after 36 h were statistically significantly in their reporting of â??no painâ? and\nâ??mild painâ? compared to patients allocated to the loxoprofen sodium group (86% vs. 66%, respectively;\np = 0.019), irrespective of gender or type of tooth extraction. However, both groups demonstrated\ncomparable (p > 0.05) post-operative pain relief over the other aforementioned allocated time intervals.\nIn conclusion, the diclofenac potassium group had slightly better control over post-operative pain\nthan the group receiving loxoprofen sodium....
Bone marrow derived mesenchymal stromal cells (BM-MSCs) have emerged as a possible\nnew therapy for Multiple Sclerosis (MS), however studies regarding efficacy and in vivo immune\nresponse have been limited and inconclusive. We conducted a phase I clinical study assessing\nsafety and clinical and peripheral immune responses after MSC therapy in MS. Seven patients with\nprogressive MS were intravenously infused with a single dose of autologous MSC (1-2 * 106 MSCs/kg\nbody weight). The infusions were safe and well tolerated when given during clinical remission. Five\nout of seven patients completed the follow up of 48 weeks post-infusion. Brain magnetic resonance\nimaging (MRI) showed the absence of new T2 lesions at 12 weeks in 5/6 patients, while 3/5 had\naccumulated new T2 lesions at 48 weeks. Patient expanded disability status scales (EDSS) were stable\nin 6/6 at 12 weeks but declined in 3/5 patients at 48 weeks. Early changes of circulating microRNA\nlevels (2 h) and increased proportion of FOXP3+ Tregs were detected at 7 days post-infusion compared\nto baseline levels. In conclusion, MSC therapy was safe and well tolerated and is associated with\npossible transient beneficial clinical and peripheral immunotolerogenic effects....
Objectives: The present randomized clinical trial assesses the six-month outcomes following\nsurgical regenerative therapy of periimplantitis lesions using either an electrolytic method (EC) to\nremove biofilms or a combination of powder spray and electrolytic method (PEC). Materials and\nMethods: 24 patients with 24 implants suffering from peri-implantitis with any type of bone defect\nwere randomly treated by EC or PEC. Bone defects were augmented with a mixture of natural bone\nmineral and autogenous bone and left for submerged healing. The distance from implant shoulder to\nbone was assessed at six defined points at baseline (T0) and after six months at uncovering surgery\n(T1) by periodontal probe and standardized x-rays. ...........................
Loading....